Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy

Full text
Author(s):
Show less -
Avansini, Simoni H. ; de Sousa Lima, Beatriz Pereira ; Secolin, Rodrigo ; Santos, Marilza L. ; Coan, Ana Carolina ; Vieira, Andre S. ; Torres, Fabio R. ; Carvalho, Benilton S. ; Alvim, Marina K. M. ; Morita, Marcia E. ; Yasuda, Clarissa L. ; Pimentel-Silva, Luciana R. ; Dogini, Danyella B. ; Rogerio, Fabio ; Cendes, Fernando ; Lopes-Cendes, Iscia
Total Authors: 16
Document type: Journal article
Source: PLoS One; v. 12, n. 4 APR 6 2017.
Web of Science Citations: 11
Abstract

Epilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting consequences. Recently, circulating microRNAs have emerged as potential biomarkers in a number of clinical scenarios. The purpose of this study was to identify and to validate circulating microRNAs that could be used as biomarkers in the diagnosis of epilepsy. Quantitative real-time PCR was used to measure plasma levels of three candidate microRNAs in two phases of study: an initial discovery phase with 14 patients with mesial temporal lobe epilepsy (MTLE), 13 with focal cortical dysplasia (FCD) and 16 controls; and a validation cohort constituted of an independent cohort of 65 patients with MTLE and 83 controls. We found hsa-miR-134 downregulated in patients with MTLE (p = 0.018) but not in patients with FCD, when compared to controls. Furthermore, hsa-miR-134 expression could be used to discriminate MTLE patients with an area under the curve (AUC) of 0.75. To further assess the robustness of hsa-miR-134 as a biomarker for MTLE, we studied an independent cohort of 65 patients with MTLE, 27 of whom MTLE patients were responsive to pharmacotherapy, and 38 patients were pharmacoresistant and 83 controls. We confirmed that hsa-miR-134 was significantly downregulated in the plasma of patients with MTLE when compared with controls (p < 0.001). In addition, hsa-miR-134 identified patients with MTLE regardless of their response to pharmacotherapy or the presence of MRI signs of hippocampal sclerosis. We revealed that decreased expression of hsa-miR-134 could be a potential non-invasive biomarker to support the diagnosis of patients with MTLE. (AU)

FAPESP's process: 13/07559-3 - BRAINN - The Brazilian Institute of Neuroscience and Neurotechnology
Grantee:Fernando Cendes
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 13/00099-7 - EEG-fMRI in the pre-operatory evaluation of patients with focal refractory epilepsies
Grantee:Ana Carolina Coan
Support type: Scholarships in Brazil - Post-Doctorate